Idiopathic pulmonary fibrosis medical therapy

Jump to navigation Jump to search

Idiopathic pulmonary fibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Idiopathic pulmonary fibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Idiopathic pulmonary fibrosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Idiopathic pulmonary fibrosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Idiopathic pulmonary fibrosis medical therapy

CDC on Idiopathic pulmonary fibrosis medical therapy

Idiopathic pulmonary fibrosis medical therapy in the news

Blogs on Idiopathic pulmonary fibrosis medical therapy

Directions to Hospitals Treating Idiopathic pulmonary fibrosis

Risk calculators and risk factors for Idiopathic pulmonary fibrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

There is currently no consensus on the treatment of IPF. Hence, none of what follows should be taken as specific advice regarding therapy, as the latter is a decision that must be made on a case-by-case basis in individual patients.[1]

There is a lack of large, randomized placebo-controlled trials of therapy for IPF. Moreover, many of the earlier studies were based on the hypothesis that IPF is an inflammatory disorder, and hence studied anti-inflammatory agents such as corticosteroids. Another problem has been that studies conducted prior to the more recent classification of idiopathic interstitial pneumonias failed to distinguish IPF/UIP from NSIP in particular. Hence, many patients with arguably more steroid-responsive diseases were included in earlier studies, confounding the interpretation of their results.

References

  1. Walter, N (2006). "Current perspectives on the treatment of idiopathic pulmonary fibrosis". Proceedings of the American Thoracic Society. American Thoracic Society. 3 (4): 330–338. PMID 16738197. Retrieved 2008-03-05. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)

Template:WH Template:WS